Original Article

You have full text access to this OnlineOpen article

Cost-effectiveness analysis of the Lyme disease vaccine

  1. Elizabeth C. Hsia†,*,
  2. James B. Chung,
  3. J. Sanford Schwartz,
  4. Daniel A. Albert

Article first published online: 6 JUN 2002

DOI: 10.1002/art.10270

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 6, pages 1651–1660, June 2002

Additional Information

How to Cite

Hsia, E. C., Chung, J. B., Schwartz, J. S. and Albert, D. A. (2002), Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis & Rheumatism, 46: 1651–1660. doi: 10.1002/art.10270

Author Information

  1. University of Pennsylvania, Philadelphia, Pennsylvania, USA

  1. †

    Dr. Hsia's work was supported by a Physician Scientist Development Award from the Arthritis Foundation.

*Division of Rheumatology, University of Pennsylvania, Maloney Building, Suite 504, 3600 Spruce Street, Philadelphia, PA 19104

Publication History

  1. Issue published online: 6 JUN 2002
  2. Article first published online: 6 JUN 2002
  3. Manuscript Accepted: 25 JAN 2002
  4. Manuscript Received: 26 MAR 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (131K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    S. A. Plotkin, Correcting a Public Health Fiasco: The Need for a New Vaccine against Lyme Disease, Clinical Infectious Diseases, 2011, 52, Supplement 3, s271

    CrossRef

  2. 2
    Kristin M Corapi, Samardeep Gupta, Matthew H Liang, Management of Lyme disease, Expert Review of Anti-infective Therapy, 2008, 6, 2, 241

    CrossRef

  3. 3
    N. Guy, Maladie de Lyme: bases fondamentales à l'origine des mesures préventives, mesures de prévention primaire et secondaire, Médecine et Maladies Infectieuses, 2007, 37, 7-8, 381

    CrossRef

  4. 4
    Kristin M Corapi, Marc I White, Charlotte B Phillips, Lawren H Daltroy, Nancy A Shadick, Matthew H Liang, Strategies for primary and secondary prevention of Lyme disease, Nature Clinical Practice Rheumatology, 2007, 3, 1, 20

    CrossRef

  5. 5
    Douglas E. Mouzin, Marianne J. Lorenzen, John D. Haworth, Vickie L. King, Duration of serologic response to three viral antigens in cats, Journal of the American Veterinary Medical Association, 2004, 224, 1, 61

    CrossRef

  6. 6
    Mallik N. Tella, Joseph Feinglass, Rowland W. Chang, Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002, Current Opinion in Rheumatology, 2003, 15, 2, 127

    CrossRef

  7. 7
    Patricia K. Coyle, Lyme disease, Current Neurology and Neuroscience Reports, 2002, 2, 6, 479

    CrossRef

  8. 8
    &NA;, Lyme disease vaccination worth it in the US?, Inpharma Weekly, 2002, &NA;, 1350, 5

    CrossRef

  9. 9
    Leonard H. Sigal, Vaccination for lyme disease: Cost-effectiveness versus cost and value, Arthritis & Rheumatism, 2002, 46, 6
    Direct Link:
View Full Article (HTML) Get PDF (131K)